Shankar Musunuri, PhD, MBA, Ocugen Chairman, CEO, and Co-Founder in conversation with Scrip
Announcing Our Submission of Emergency Use Authorization Request to the US FDA for COVAXIN™ (BBV152) Candidate for 2-18 Years
Ocugen Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate
FDA Accepts OCU400 IND Application Supporting Phase 1/2 Clinical Trial
Mission - General
Our Mission is to Develop
Gene Therapies to Cure Blindness
Diseases and Develop a Vaccine
to Save Lives from COVID-19
previous arrowprevious arrow
next arrownext arrow
Sign up to receive email alerts with the latest news from Ocugen Subscribe